GT200600001A - Uso de colorantes de cianina para el diagnostico de enfermedades proliferativas - Google Patents

Uso de colorantes de cianina para el diagnostico de enfermedades proliferativas

Info

Publication number
GT200600001A
GT200600001A GT200600001A GT200600001A GT200600001A GT 200600001 A GT200600001 A GT 200600001A GT 200600001 A GT200600001 A GT 200600001A GT 200600001 A GT200600001 A GT 200600001A GT 200600001 A GT200600001 A GT 200600001A
Authority
GT
Guatemala
Prior art keywords
diagnosis
proliferative diseases
cyanine
colors
cyanine colors
Prior art date
Application number
GT200600001A
Other languages
English (en)
Inventor
Kai Licha
Michael Schirner
Martin Pessel
Malte Bahner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200600001(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200600001A publication Critical patent/GT200600001A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032Methine dyes, e.g. cyanine dyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032Methine dyes, e.g. cyanine dyes
    • A61K49/0034Indocyanine green, i.e. ICG, cardiogreen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058Antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL USO DE LA CIANINA SF64, 529, 536 Y/O 541 PARA EL DIAGNOSTICO DE ENFERMEDADES PROLIFERATIVAS, EN PARTICULAR ENFERMEDADES CON TUMORES, CON LA ADMINISTRACION DE MENOS DE 0,1 MG/KG DE PESO CORPORAL.
GT200600001A 2005-01-07 2006-01-04 Uso de colorantes de cianina para el diagnostico de enfermedades proliferativas GT200600001A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05000276A EP1679082A1 (en) 2005-01-07 2005-01-07 Use of cyanine dyes for the diagnosis of proliferative diseases

Publications (1)

Publication Number Publication Date
GT200600001A true GT200600001A (es) 2006-08-22

Family

ID=34933224

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600001A GT200600001A (es) 2005-01-07 2006-01-04 Uso de colorantes de cianina para el diagnostico de enfermedades proliferativas

Country Status (23)

Country Link
EP (2) EP1679082A1 (es)
JP (1) JP5578765B2 (es)
KR (1) KR20070092270A (es)
CN (1) CN101128218A (es)
AR (1) AR052190A1 (es)
AU (1) AU2006204496A1 (es)
BR (1) BRPI0606411A2 (es)
CA (1) CA2594390C (es)
CR (1) CR9232A (es)
DO (1) DOP2006000005A (es)
GT (1) GT200600001A (es)
IL (1) IL182499A0 (es)
MX (1) MX2007008300A (es)
NO (1) NO20074036L (es)
NZ (1) NZ554917A (es)
PA (1) PA8659101A1 (es)
PE (2) PE20060872A1 (es)
RU (1) RU2007129919A (es)
TW (1) TW200635612A (es)
UA (1) UA89976C2 (es)
UY (1) UY29323A1 (es)
WO (1) WO2006072580A1 (es)
ZA (1) ZA200706533B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004009169D1 (de) * 2004-07-22 2007-11-08 Bayer Schering Pharma Ag Verwendung von Cyanin-farbstoffen zur Diagnose von Krankheiten, welche mit Angiogenese assoziert sind
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases
EP1745739A3 (en) * 2005-07-14 2009-04-22 Bundesrepublik Deutschland, vertr. d.d. Bundes- ministerium f. Wirtschaft- und Technologie, dieses vertr. d.d. Präs. d. Phys.-Techn. Bundesanstalt Optical imaging of rheumatoid arthritis
CN101636412A (zh) * 2007-03-30 2010-01-27 霍夫曼-拉罗奇有限公司 标记的和非标记的单克隆抗体的组合物
US20110262354A1 (en) 2007-07-13 2011-10-27 Emory University Cyanine-containing compounds for cancer imaging and treatment
GB0803477D0 (en) 2008-02-26 2008-04-02 Ge Healthcare As Therapy selection method
WO2009152440A1 (en) * 2008-06-13 2009-12-17 Cedars-Sinai Medical Center Small molecule ligand-drug conjugates for targeted cancer therapy
GB0814960D0 (en) * 2008-08-15 2008-09-24 Ge Healthcare As Method for detecting dysplasia
US20120226119A1 (en) 2009-07-09 2012-09-06 Hoffmann-La Roche Inc. Vivo tumor vasculature imaging
CA2768330A1 (en) 2009-07-28 2011-02-03 F. Hoffmann-La Roche Ag Non-invasive in vivo optical imaging method
EP2470887B1 (en) 2009-08-28 2020-03-11 VisEn Medical, Inc. Systems for tomographic imaging in diffuse media using a hybrid inversion technique
JP2011046662A (ja) 2009-08-28 2011-03-10 Fujifilm Corp 近赤外蛍光造影剤
JP2011046663A (ja) * 2009-08-28 2011-03-10 Fujifilm Corp 近赤外蛍光造影剤
CN102781307B (zh) 2009-09-22 2016-01-20 文森医学公司 用于漫射性介质虚拟折射率匹配的系统和方法
MX2012012736A (es) 2010-05-07 2013-02-26 Hoffmann La Roche Metodo de diagnostico para la deteccion de celulas ex vivo.
WO2012119999A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag Means and methods for in vivo testing of therapeutic antibodies
JP6385060B2 (ja) 2011-03-07 2018-09-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 治療的に活性な抗体のインビボにおける選択
KR101373108B1 (ko) 2012-01-20 2014-03-27 이화여자대학교 산학협력단 폴리메틴 체인에 메조-반응작용기를 갖는 신규한 시아닌 유도체 및 이의 제조방법
CN102608051B (zh) * 2012-02-21 2015-04-08 中国科学院化学研究所 用于诊断白血病的试剂盒
CN102703569B (zh) * 2012-05-24 2014-04-09 中国科学院化学研究所 菁染料的新用途
CN102706787B (zh) * 2012-05-24 2015-04-08 中国科学院化学研究所 菁染料的新用途
WO2014062716A1 (en) 2012-10-15 2014-04-24 Visen Medical, Inc. Systems, methods, and apparatus for imaging of diffuse media featuring cross-modality weighting of fluorescent and bioluminescent sources
US20150182518A1 (en) 2012-10-26 2015-07-02 Canon Kabushiki Kaisha Cancer cell inhibitory drug and cancer stem-cell detection probe
US20150367004A1 (en) * 2012-12-10 2015-12-24 Molecular Targeting Technologies, Inc. Compositions and methods of diagnosing ocular diseases
JP6681334B2 (ja) 2013-12-31 2020-04-15 メモリアル スローン ケタリング キャンサー センター リアルタイムの蛍光源のマルチチャネル撮像のためのシステム、方法、および装置
RU2565645C1 (ru) * 2014-09-05 2015-10-20 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ рентгендиагностики глубины инвазии рецидива рака вульвы в мягкие ткани
CA2970719C (en) 2014-12-15 2023-08-01 Memorial Sloan Kettering Cancer Center Cyclic peptides with enhanced nerve-binding selectivity, nanoparticles bound with said cyclic peptides, and use of same for real-time in vivo nerve tissue imaging
CN108495655A (zh) 2015-12-15 2018-09-04 纪念斯隆凯特琳癌症中心 用于组织区分例如用于术中可视化的成像系统和方法
KR20190090394A (ko) 2016-11-30 2019-08-01 메모리얼 슬로안 케터링 캔서 센터 억제제-작용화된 초소형 나노입자 및 이의 방법
CA3095410A1 (en) 2018-03-30 2019-10-03 Perkinelmer Health Sciences, Inc. Systems and methods for 3d reconstruction of anatomical organs and inclusions using short-wave infrared (swir) projection tomography
EP4015004A1 (en) 2020-12-18 2022-06-22 Phi Pharma SA Proteoglycan specific branched peptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000095758A (ja) * 1998-09-18 2000-04-04 Schering Ag 近赤外蛍光造影剤および蛍光造影方法
DE19917713A1 (de) * 1999-04-09 2000-10-19 Diagnostikforschung Inst Kurzkettige Peptid-Farbstoffkonjugate als Konstrastmittel für die optische Diagnostik
DE19947559A1 (de) * 1999-09-24 2001-04-19 Schering Ag Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
ATE409209T1 (de) * 2003-01-24 2008-10-15 Bayer Schering Pharma Ag Hydrophile, thiolreaktive cyaninfarbstoffe und deren konjugate mit biomolekülen für fluoreszenzdiagnose
DE602004009169D1 (de) * 2004-07-22 2007-11-08 Bayer Schering Pharma Ag Verwendung von Cyanin-farbstoffen zur Diagnose von Krankheiten, welche mit Angiogenese assoziert sind
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases

Also Published As

Publication number Publication date
ZA200706533B (en) 2009-07-29
PE20100449A1 (es) 2010-07-25
NO20074036L (no) 2007-08-03
RU2007129919A (ru) 2009-02-20
KR20070092270A (ko) 2007-09-12
BRPI0606411A2 (pt) 2009-06-23
NZ554917A (en) 2010-01-29
EP1833513A1 (en) 2007-09-19
CA2594390C (en) 2013-10-22
MX2007008300A (es) 2007-09-07
TW200635612A (en) 2006-10-16
CR9232A (es) 2007-11-23
AR052190A1 (es) 2007-03-07
JP5578765B2 (ja) 2014-08-27
AU2006204496A1 (en) 2006-07-13
UA89976C2 (ru) 2010-03-25
WO2006072580A1 (en) 2006-07-13
PE20060872A1 (es) 2006-10-01
DOP2006000005A (es) 2006-07-15
CA2594390A1 (en) 2006-07-13
EP1833513B1 (en) 2013-03-06
UY29323A1 (es) 2006-10-02
PA8659101A1 (es) 2006-09-08
JP2008526802A (ja) 2008-07-24
EP1679082A1 (en) 2006-07-12
CN101128218A (zh) 2008-02-20
IL182499A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
GT200600001A (es) Uso de colorantes de cianina para el diagnostico de enfermedades proliferativas
DOP2007000102A (es) Arilimidazolonas y ariltriazolona sustituidas asi como su uso
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
GT200600046A (es) Terapia de combinacion
SG158870A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
CL2007002891A1 (es) Trans-5-cloro-2-metil-2,3,3a,12b-tetrahidro-1h-dibenz-[2,3:6,7]oxepino[4,5-c]pirrol 50% amorfo en base al peso total del compuesto; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de un trastorno seleccionado entre e
HN2011001593A (es) Piridiloxi-indoles del vegf-r2 y uso de los mismos para el tratmiento de enfermedades
SV2006002473A (es) Forma cristalina ortorrombica del maleato de asenapina y su uso en el tratamiento de trastornos mentales ref. 2005.893 (806.671)
CL2007002708A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
GT200500191A (es) Derivados de pirido - pirimidina, su preparacion, su aplicacion en terapeutica
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
TW200731987A (en) Cytotoxicity mediation of cells evidencing surface expression of CD44
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas
DOP2006000280A (es) Nuevos derivados de furopirimidina acíclicos sustituidos y su uso
WO2007095729A8 (en) Cytotoxicity mediation of cells evidencing surface expression of cd63
GT200600106A (es) Agentes endoparasiticidas
TW200637875A (en) Cytotoxicity mediation of cells evidencing surface expression of CD63
HN2005030779A (es) Nonadepsipeptidos acilados ii
MA31630B1 (fr) Dérivés de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides et de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazépine-7-carboxamides, leur préparation et leur application en thérapeutique
PE20070435A1 (es) Formulacion farmaceutica que comprende temozolomida y un inhibidor de la proteina quinasa
UY31903A (es) 7-sulfanilmetil-,7-silfinilmetil-y7-sulfonilmetilindoles sustituidos y el uso de los mismos
CL2004000535A1 (es) Composicion farmaceutica que comprende rapamicina o un derivado de rapamicina y pimecrolimus; y su uso para el tratamiento de enfermedad inflamatoria del intestino.
BRPI0507811A (pt) derivados de 7h-pirrolopirimidina
BRPI0414527A (pt) tratamento de tumores estromáticos gastrointestinais com imatinib e midostaurina
GT200400212A (es) Agentes para la reduccion de peso